{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:49:05Z","timestamp":1792558145318,"version":"4.5.0"},"reference-count":9,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,4,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>Patients were monitored for a minimum of 5 years after completion of study treatment for the time-to-event end points of progression-free survival (PFS), event-free survival, duration of response, and overall survival per investigator assessment. Data on the number of patients who received second-line anticancer treatment and the occurrence of other malignancies were also collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The medians were not reached for any of the time-to event end points for either the BR or R-CHOP\/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment group and 55.8% in the R-CHOP\/R-CVP group. The difference in PFS was considered significant with a hazard ratio of 0.61 (95% CI, 0.45 to 0.85; P = .0025). The hazard ratio for event-free survival and duration of response ( P = .0020 and .0134, respectively) also favored the BR regimen over R-CHOP\/R-CVP. However, no significant difference in overall survival was observed. The overall safety profiles of BR, R-CHOP, and R-CVP were as expected; no new safety data were collected during long-term follow-up. A higher number of secondary malignancies was noted in the BR treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Overall, BR demonstrated better long-term disease control than R-CHOP\/R-CVP and should be considered as a first-line treatment option for patients with indolent and mantle-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.18.00605","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T15:57:26Z","timestamp":1551283046000},"page":"984-991","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":279,"title":["First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study"],"prefix":"10.1200","volume":"37","author":[{"given":"Ian W.","family":"Flinn","sequence":"first","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"van der Jagt","sequence":"additional","affiliation":[{"name":"Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wood","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, Woolloongabba, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simpson","sequence":"additional","affiliation":[{"name":"North Shore Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Kolibaba","sequence":"additional","affiliation":[{"name":"US Oncology Research, Vancouver, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Issa","sequence":"additional","affiliation":[{"name":"Middlemore Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chang","sequence":"additional","affiliation":[{"name":"University of Wisconsin Hospitals and Clinics, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Hallman","sequence":"additional","affiliation":[{"name":"Teva Global Clinical Operations, Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Teva Biometrics Operations, Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"US Oncology Research, The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7500"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"B6","first-page":"484","volume":"130","author":"Kahl B","year":"2017","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2478-9"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0388"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-516815"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.08.029"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.18.00605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:10:08Z","timestamp":1653797408000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.18.00605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,20]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,4,20]]}},"alternative-id":["10.1200\/JCO.18.00605"],"URL":"https:\/\/doi.org\/10.1200\/jco.18.00605","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,20]]},"assertion":[{"value":"2019-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}